Reuters :: Small Business News

Myriad Genetics swings to Q4 profit on license payment

(Reuters) - Myriad Genetics Inc swung to a quarterly net profit, helped by a one-time upfront license payment, and added that it is considering strategic options, including a possible separation of its molecular diagnostic business from pharmaceutical business.<div class="feedflare"> <a href="http://feeds.reuters.com/~f/reuters/smallBusinessNews?a=a2nRIK"><img src="http://feeds.reuters.com/~f/reuters/smallBusinessNews?i=a2nRIK" border="0"></img></a> <a href="http://feeds.reuters.com/~f/reuters/smallBusinessNews?a=NTHHqk"><img src="http://feeds.reuters.com/~f/reuters/smallBusinessNews?i=NTHHqk" border="0"></img></a> <a href="http://feeds.reuters.com/~f/reuters/smallBusinessNews?a=eBSKck"><img src="http://feeds.reuters.com/~f/reuters/smallBusinessNews?i=eBSKck" border="0"></img></a> </div><img src="http://feeds.reuters.com/~r/reuters/smallBusinessNews/~4/369021406" height="1" width="1"/>